A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer

Trial Profile

A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALTER0303
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 18 Oct 2017 Results investigating the connection between activated circulating endothelial cells and PFS, OS and metastases burden in the ALTER0303 trial presented at the 18th World Conference on Lung Cancer
    • 18 Oct 2017 Results reporting the main impact factors affecting the efficacy and prognosis of anlotinib based on the data from ALTER0303 to elucidate the most benefit population (n=294) presented at the 18th World Conference on Lung Cancer
    • 18 Oct 2017 Results of an Exploratory Subgroup Analysis assessing the efficacy of anlotinib in patients with or without EGFR gene mutations presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top